AIVF, the Israeli developer of the first AI-based IVF software platform, has announced the acquisition of ART Compass, an application for the management of the IVF laboratory.
The company says the acquisition of ART Compass will expand its offering and create traction in the US.
AIVF’s flagship product, EMA, is an AI software platform that delivers automated and actionable insights to optimise the fertility journey.
“This first acquisition adds novel capabilities for the expansion and integration of our FertilityOS in clinics,” said Daniella Gilboa, AIVF CEO and co-founder.
“Strategic industry partnerships like this support our mission to accelerate the digital transformation of fertility care.”
Dr Carol Lynn Curchoe, founder of ART Compass, said: “The ART Compass application is a first step toward digitalisation of the unstructured, complex, and often ‘on paper’ data in the IVF lab.
“It is a perfect fit to be part of the advanced AI-powered platform that AIVF is bringing to global fertility clinics.”
Dr Curchoe will take the position of director of medical affairs at AIVF.
Integration of ART Compass into the EMA platform for fertility clinics is planned for the first quarter of 2023.
The news comes four months after the medtech company announced it raised US$25 million to expand its work force and advance digital fertility care.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.
